NSDHL and familial pancreatic carcinoma: Treatment with atorvastatin or NSDHL knockout activates SREBP1, which promotes TGF-β1 expression and induces a canonical Smad2 and Smad3 effector cascade, resulting in the induction of epithelial-mesenchymal transition in pancreatic cancer [16].